AusVaxSafety collected safety data from infants who received Beyfortus (nirsevimab), a long-acting monoclonal antibody given by injection to help prevent severe respiratory syncytial virus (RSV) disease in infants. Nirsevimab immunisation programs varied across Australian states and territories.

Safety data were collected through existing AusVaxSafety surveillance sites, primarily general practices, that administered nirsevimab. The data presented on this page are based on responses from parents and carers who completed an AusVaxSafety survey in the days following their child's nirsevimab immunisation.

These data provide a profile of what to expect in the days following nirsevimab immunisation and can assist parents and carers in planning for immunisation.

AusVaxSafety's active vaccine safety surveillance system complements the safety surveillance activities of the Therapeutic Goods Administration.

Further information and resources on RSV prevention products are available on the National Centre for Immunisation Research and Surveillance (NCIRS) RSV webpage.